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Background: To date, non arteritic anterior ischemic optic neuropathy (NAION) is still incurable. We wish to
evaluate the effect of intravenous (IV) corticosteroids on the visual outcome of NAION patients.
Methods: Visual parameters were retrospectively compared between NAION patients treated with IV corticosteroids
and untreated NAION patients (control). Visual acuity (VA) and Humphrey automated static perimetry visual field
(VF) defects of the affected eye were compared between groups at baseline, 1, 3, 6 months, and end of follow-up
visits. The VF analysis consisted of number of quadrant involvements and mean deviation (MD).
Results: Each group comprised 23 patients (24 eyes). Mean initial VA was similar in the control and treatment
groups (p = 0.8). VA at end of follow-up did not improve in either groups (p = 0.8 treated group, p = 0.1 control
group). No improvement and no difference in VF defects were found by either quadrant analysis (p = 0.1 treated
group, p = 0.5 control group) or MD analysis (p = 0.2, treated group, p = 0.9 control group). VA and VF parameters
tended to be worse in the treated group, although without statistical significance.
Conclusions: Our results suggest that IV corticosteroids may not improve the visual outcome of NAION patients.
Since intravenous corticosteroids could potentially cause serious adverse effects, this treatment for NAION is
questionable.
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Nonarteritic ischemic optic neuropathy (NAION) is the
most common cause for acute optic neuropathy in adults
over the age of 50 [1]. It is believed to be the result of is-
chemic damage to the anterior optic nerve that is predom-
inantly supplied by the posterior ciliary arteries [2,3]. Most
patients present with acute unilateral painless visual defect
involving mainly, but not only, the inferior visual field. To
date, there is no generally accepted, well-proven, effective
treatment for this condition. The only randomized control
study for the treatment of NAION was the IONDT (Ische-
mic Optic Neuropathy Decompression Trial) [4] which* Correspondence: mkinori@hotmail.com
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NAION patients is ineffective, and may even be harmful.
Other studies explored the role of aspirin [5-7], vasodila-
tors [8], heparin-induced extracorporeal LDL/fibrinogen
precipitation (HELP) [9], hyperbaric oxygen [10], diphenyl-
hydantoin [11], norepinephrine [12], levodopa [13], topical
brimonidine [14,15], intravitreal bevacizumab [16,17] and
systemic corticosteroids [18-20]. Recently Prokosch et al.
showed that adding the corticosteroid floucortolone to
their standard treatment (intravenous and per os pentoxi-
fylline for one week and then per os for a further 6 months)
slightly improves the short and long term visual acuity
(VA) in some patients. However, visual field (VF) was not
improved in either group [20].
The rationale behind corticosteroid treatment, although
not proven, is the thought that faster resolution of optic
disc edema may be associated with better visual outcome
[21]. The presumed mechanism for corticosteroids improvetd. This is an Open Access article distributed under the terms of the Creative
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“vicious circle” [19] in which the ischemic tissue further
suffers from the secondary damage by a mechanical pres-
sure caused by the swollen ischemic axons in an already
crowded disc with a small scleral canal. This would not
prevent the primary insult but should theoretically limit
the secondary insult. Reducing capillary permeability in
the optic disc by corticosteroids [21] could be another
mechanism.
Recently, Hayreh reported a very large study carried
out over a period of 27 years [19]. This study comprised
NAION patients who were treated with systemic oral
corticosteroids as opposed to untreated NAION pa-
tients. Although the reported results favored treatment
with 80 milligram prednisone for 2 weeks with subsequent
tapering, with regard to VA and VF performances, it is still
not widely accepted. In fact, a thought-provoking discus-
sion in the literature was recently conducted on this issue
[19,22,23].
No controlled studies of megadose intravenous (IV) cor-
ticosteroids (1 gr/day methylprednisolone) for NAION
have been performed. Some clinicians tend to recommend
this approach in severe progressive cases in order to de-
crease the secondary neural damage, despite no suppor-
ting evidence in the literature [3].
This study was conducted to explore the visual outcome
in NAION patients treated with IV corticosteroids as com-
pared to untreated patients, and to report the adverse ef-
fects of such treatment.Methods
The study was approved by the local Ethics Committee of
The Chaim Sheba Medical Center, Tel Hashomer, Israel.
We conducted a retrospective chart review of all patients
diagnosed as NAION according to the IONDT criteria:
Sudden loss of vision within the previous 14 days, a rela-
tive afferent pupillary defect, optic disc edema and an ab-
normal VF consistent with optic neuropathy. The only
exception was the VA parameter in the IONDT study (20/
64 or less in the affected eye) which was not applied in
our study. The arteritic type of ischemic optic neuropathy
(A-AION) was ruled out in all patients using clinical and
laboratory data, mainly erythrocyte sedimentation rate, C-
reactive protein and blood count. Inclusion criteria were: 1)
Diagnosis of NAION according to IONDT [4] 2) Rapidly
progressive NAION; or 3) Poor vision in the contralateral
eye. Exclusion criteria were: 1) Previously documented ret-
inal conditions that could influence VA, such as severe non-
proliferative, or proliferative diabetic retinopathy. Patients
with mild nonproliferative diabetic retinopathy were in-
cluded; 2) Glaucoma patients with documented previous
VF defects; 3) Patients with follow-up period of less than
6 months, and 4) Patients with unreliable VFs.All patients were examined at the Neuroophthalmology
Clinic in the Chaim Sheba Medical Center, Israel. Patients
with progressive NAION, or poor vision in the contralateral
eye without a major systemic condition, such as uncon-
trolled hypertension, uncontrolled diabetes, or congestive
heart failure were offered treatment with IV corticosteroids
protocol as performed in the optic neuritis treatment trial
(ONTT) [24]. All patients in the intervention group had to
sign an informed consent before treatment, which was
given within 2 weeks of onset. The control group included
patients with NAION who refused the treatment or those
who had systemic contraindications for corticosteroid treat-
ment. We made efforts to include in the control group pa-
tients with similar characteristics as the treated group (e.g.
age, gender, number of cardiovascular risk factors, aspirin
use and crowded disc).
Data for analysis included examinations conducted at
baseline, 1, 3, 6 months, and end of follow-up. Visual pa-
rameters were assessed by VA using the standard Snellen
acuity chart (converted to LogMAR for statistical analysis),
and Humphrey automated static perimetry for VF defects.
The latter were graded by two methods: a) a scale of 0 to
4 (0 being a normal field and 4 being a defect involving
four quadrants); b) mean deviation (MD).
Statistical analysis of the data was performed by Student’s
t test for continuous variables (such as VA and MD) and
Fisher’s exact test for categorical variables (such as number
of quadrant involvement in VF) ± values represent standard
deviation.
Results
Main demographic and clinical data of the study popula-
tion is depicted in Table 1. Groups were similar regarding
age, gender, contralateral optic disc appearance and the
presence of vascular risk factors. Follow-up was slightly
longer for the control group (mean, 36 months versus
22 months in the treatment group). Mean initial VA was
20/70 (LogMAR 0.54 ± 0.67) in the treated group and 20/
69 (LogMAR 0.54 ± 0.49) in the control group (p = 0.8).
Results of VA performances over time for both groups are
shown in Figure 1. In the control group VA remained the
same at all-time points other than at 3 months after base-
line where a slight improvement was seen. However, this
improvement was probably clinically insignificant (average
improvement from 20/66 to 20/53, p = 0.04). Moreover,
after Bonferroni correction for multiple comparisons this
results turned out to be insignificant (p = 0.12). In the IV
treated group the average VA also remained the same, but
with a trend towards an exacerbated final VA compared to
the control group. The average VA at end of follow-up
was 20/80 (0.60 in LogMAR) in the treated group and 20/
53 (0.42 in LogMAR) in the control group (p = 0.3).
Figure 2 shows the outcome for VF according to quad-
rants involved and the average MD. The initial VF showed
Table 1 Main demographic and clinical data of the






Male: female 14:10 16:8 0.55
Age (years) 54.4 ± 12.3 55.4 ± 9.6 0.78
Follow-up (months) 22.7 ± 23.4 36.2 ± 24.2 0.04
Number vascular risk factors* 1.4 ± 1.1 1.6 ± 1.1 0.60
Crowded disc 10 (42%) 13 (54%) 0.31
Mean VA (LogMAR) 0.54 ± 0.67 0.54 ± 0.49 0.80
Visual field parameters
Mean quadrant involvement 2.4 ± 0.8 2.0 ± 0.6 0.007
Mean MD 9.7 ± 10.4 9.3 ± 10.5 0.9
VA = Visual acuity, MD =Mean deviation.
*Includes: Hypertention, diabetes mellitus, ischemic heart disease, dyslipidemia
and smoking.
Figure 1 Visual acuity (VA) in LogMAR units in the control
group (upper) and IV methylprednisolone treated group.
Value above lines represents p-value of mean LogMAR VA compared
to mean baseline VA at different time points. Baseline mean VA was
the same in both groups: Log MAR 0.54 (equals to 20/70). The final
VA was not statistically different form baseline in both groups: 0.43
(equals to 20/53) in the control group (p = 0.1 compared to baseline)
and 0.61 (equals to 20/80) in the treated group (p = 0.8 compared to
baseline). Note a very mild trend toward VA improvement in the
control group versus worsening in the treated group, although
statistically not significant.
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rants in the control group. This difference was statistically
significant (p = 0.007), and could be explained by the bias
of the clinician to treat the more severe cases with IV cor-
ticosteroids. As shown, VF defect severity remained the
same in both groups throughout the follow-up period. At
final visit, quadrant involvement was 2.6 ± 0.9 in the treated
group and 2.2 ± 0.7 in the control group (p = 0.07). In both
groups mean VF quadrant involvement was not statistically
significant from baseline in all examinations. The VF de-
fects according to MD analysis showed no statistically sig-
nificant difference in the initial MD value between groups
(p = 0.9), as opposed to analysis by quadrants. No statistical
difference was found between groups at the end of follow-
up (p = 0.2).
Drug-related side effects in the treated group were min-
imal and observed in four patients: two patients suffered
from a temporary increase in their blood glucose levels,
one had myalgia, and one suffered from stomachaches.
Discussion
Lack of available treatment for patients with NAION is a
source of discomfort for the neuroophthalmologist. Vari-
ous agents and procedures for NAION treatment have
been suggested, but most without encouraging results.
The idea of treating NAION with corticosteroids is that
relieving the pressure on the axons during the acute phase
(when the optic disc is edematous) may prevent further
damage to the optic nerve. Therefore, in most studies cor-
ticosteroids were administered in the acute phase, which
is believed to be within the first 2 weeks [19]. This thera-
peutic window is also supported by animal models [25] as
well as the common clinical experience of general progres-
sion in visual loss during this period, with stabilization
thereafter [3]. For this reason the IONDT [4] also allowed
a 2-week therapeutic window for the decompression to bemade (for regular-entry patients). In our study all patients
also received treatment within 2 weeks of onset.
The largest series to date reporting corticosteroid treat-
ment for NAION [19], was conducted over a period of
27 years. This study included 613 NAION patients who
were almost equally divided into two groups, oral cortico-
steroid treatment versus no treatment. Results showed that
treatment was more beneficial: VA improved in 70% of the
Figure 2 Humphrey visual field (HVF) analysis in quadrants (upper graphs) and according to the mean deviation (MD) (lower graphs).
Value above columns represents the p-value of mean quadrant involvement (upper graphs) and mean MD value (lower graphs) compared to
baseline. Note that in both groups there was no change in the number of quadrant involvement at any time point. Analysis by MD showed no
statistically significant difference in both groups between baseline and final values (p = 0.9 for controls, p = 0.2 for treated group). Note a mild
trend toward improvement in the control group versus worsening in the treated group in the MD analysis. This trend was not shown in the
analysis by quadrants involvement. *After bonferroni correction for multiple comparisons: p = 0.12.
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Moreover, VF improved in 40% in the treated group versus
25% in the untreated group. The results were similar
after 6 months and 1 year, which led the authors to con-
clude that treating NAION patients in the acute phase
of the disease, and the sooner the better, is of major
benefit, especially for patients with lower baseline per-
formances. Admirable, we suspected that our clinical
experience with NAION patients treated with systemic
corticosteroids is less encouraging, similar to the report
of Rebolleda et al. [26].
The aim of our study was to evaluate whether IV cor-
ticosteroids are beneficial for NAION patients. It is
feasible that if the optic nerve could be “saved” from
the secondary damage caused by inflammation [27],
and the mechanical damage caused by the swelling it-
self, a boost of IV corticosteroids (as opposed to oral
treatment) would be more efficient, as was found for
optic neuritis in the ONTT [4]. Our results were disap-
pointing in that IV corticosteroids for NAION im-
proved neither the VA nor the VF of NAION patients
compared to untreated patients.
Of further concern is the list of systemic side effects of
corticosteroids and significance of diabetes instability,hypertensive crisis, weight gain and mood instability (al-
though these conditions were not clearly shown in our
small group) when dealing with a population that initially
is at risk, even when on occasion the classic cause-effect
relationship is not so obvious. Hence we believe that com-
prehensive treatment of NAION patients with systemic
corticosteroids will be acceptable only when a large, pro-
spective, randomized, multicenter study will prove the
clear benefit of treatment, as was shown in the ONTT for
optic neuritis.
Unfortunately, there are many limitations to our
study. The major limitation is the retrospective nature
of this study which does not allow deducing clear conclu-
sions about corticosteroid treatment for NAION. Another
major limitation is the relatively small group of patients.
Furthermore, only patients with poor visual parameters, as
well as those with low vision in the fellow eye were offered
IV corticosteroid treatment which leads to a selection bias.
Moreover, the control group included also patients with
contraindications for steroid treatment, such as uncon-
trolled diabetes or hypertension, which can potentially
worsen the final visual results. The power of our study
is its relatively long follow-up and matched controls, as
far as can be performed retrospectively.
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In summary, our data, with the major limitations stated
above, does not suggest the superiority of IV steroid treat-
ment over no treatment. As intravitreal corticosteroid
treatment for NAION is still anecdotal [28,29], any steroid
protocol for NAION patients should be used judicially. In
our center, based on our experience, we chose to abandon
the use of IV corticosteroids for NAION patients until a
randomized control trial will prove the benefit of such
treatment.
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